DRUGS FOR PEPTIC ULCER

INTRODUCTION AND CLASSIFICATION

Speaker- Mariya Taiyyab (42)

Made by- Mamta Rautela (38)
Manish Kumar (39)
Manjeet Kaur (40)
Mantasha Khan (41)
Kajal Tomar (43)
PEPTIC ULCER

 Peptic ulcer is a break in the gastric or duodenal

mucosa that arises when the normal mucosal defensive
factors are impaired or are overwhelmed by aggressive
luminal factors such as acid and pepsin.

 By definition, ulcers extend through the muscularis

mucosae and are usually over 5 mm in diameter.
EPIDEMIOLOGY
 In the United States, there are about 500,000 new cases per year of peptic ulcer
and 4 million ulcer recurrences
 Ulcers occur slightly more commonly in men than in women (1.3:1).

 Ulcers occur five times more commonly in the duodenum, where over 95%
are in the bulb or pyloric channel.

 In the stomach, benign ulcers are located most commonly in the antrum (60%)
and at the junction of the antrum and body on the lesser curvature (25%).

 Ulcers are more common in smokers and in patients taking NSAIDs on a

long-term basis.
PATHOGENESIS
 Mucosal defense forces
• Surface mucosal • Bicarbonate
secretion secretion
system
transport
Mucosal cell
blood flow epithelial
Apical

e capacity Elaboration
regenerativ of
Epithelial prostaglandi
n
• Elaboration of
prostaglandin
Mucosal defence
mechanism
Aggressive forces

H.Pylori
NSAIDS
infection

Corticosteriods cigarette

alcohol
Associated disease

Chronic renal
Cirrhosis
failure

Chronic lung Chronic

disease pancreatitis

Zollinger
ellison
syndrome
MANAGEMENT
 Endoscopic
procedures are
investigation
of choice.
 Goals of antiulcer therapy

 Relief of pain
 Ulcer healing
 Prevention of complications (bleeding, perforation)
 Prevention of relapse
Approaches for treatment of peptic
ulcer
Reduction of Neutralisation
gastric acid of gastric
secretion acid(antacids)

Ulcer Anti H.pylori

protectives drugs
Reduction of gastric acid secretion
 Proton pump inhibitors: Omeprazole, esmoprazole,
lansoprazole, pantaprazole, rabeprazole,
dexrabeprazole.

 H2 antihistaminics : Cimetidine, Ranitidine,

famotidine, roxatidine.

 Anticholinergic drugs: pirenzepine, propantheline,

oxyphenonium.

 Prostaglandin analogues: misoprostol

 ANTACIDS

Systemic Non-systemic

Sod. Bicarbonate, Mag. Hyroxide, Mag. trisilicate

Al. hydroxide gel,
Sod.citrate Magaldrate,
Calcium carbonate
 • Sucralfate
• Colloidal bismuth subcitrate
ULCER
PROTECTIVES

• Amoxicillin
ANTI • Clarithromycin
• Tetracycline
H-PYLORI • Metronidazole/tinidazole
MECHANISM OF ACID SECRETION
 Physiological acid secretion
 Parietal cells are main site of acid secretion in stomach
 Hydrogen potassium pump secretes H+ ions in the apical
canaliculi of parietal cells by follwing secretogouges:
1. Histamine
2. Gastrin
3. Acetylcholine
DRUGS FOR REDUCTION OF GASTRIC
ACID SECRETION

SPEAKER :Komalpreet Kaur(37)

MADE BY: Marut Arora (44)
Mayank Pahwa (45)
Mridani Purohit (51)
 Proton Pump Inhibitors
 Omeprazole is the prototype member of substituted benzimidazole

which inhibits the final step in gastric acid secretion.

 There is dose dependent suppression of gastric acid secretion without

anti cholinergic or H2 blocking action.

 It is a powerful inhibitor of gastric acid and can totally abolish HCl

secretion.

 It is inactive at natural pH.

 Mechanism of action
At pH less than 5 it rearranges to two cationic forms(sulfenic
acid and sulfenamide)

Reacts with SH group of H/K ATPase pump and inactivates it

irreversibly

They get concentrated in acidic Ph of canaliculi as the charged

form are enable to diffuse back
 Pharmacokinetics
 Route: orally in enteric coated form to protect them from gastric acid

juice.

 Oral bioavailability :50% due to acid liability.

 Bioavailability is reduced by food

 They should be taken empty stomach, followed 1 hour later by a meal to

activate H+K+ ATPase and make it more susceptible to PPI.

 Highly plasma protein bound

Metabolized in liver by CYP2C19 and CYP3A4.

Inhibition of HCl secretion occurs within 1 hr ; max -2 hr ; half maximal

-24hrs and lasts for 2-3 days

At steady state all PPI’s produce 80-90% suppression of 24 hr acid

output with conventional doses .

These are HIT and RUN drugs

Secretion resumes gradually over 3-5 days of stopping the drug .
 ADVERSE EFFECTS
 PPIs produce minimal adverse effects .
 Nausea ,loose stools ,headache ,abdominal pain ,muscle pain and
joint pain ,dizziness are complained by 3-5%.
 Rashes ,leucopenia and hepatic dysfunction are infrequent .
 Prolonged treatment atrophic gastritis reported occasionally.
 No harmful effects of PPIs during pregnancy are known .
 PPIs have often been used for gerd during pregnancy
 ESOMEPRAZOLE LANSOPRAZOLE PANTOPRAZOLE RABEPRAZOLE

• S enantiomer of
 More potent than
omeprazole .  Newer PPI is claimed to
omeprazole .
• Similar potency and cause faster acid
• Higher bioavailability clinical efficacy to suppression.
 Inhibition of
omeprazole ,but is more
H+K+ATPase is partly
• Slower elimination . acid stable and has higher  Due to higher pKa,it is
reversible.
bioavailability. more rapidly converted
• Longer t1/2. to the active species.
 Higher oral availability .
• Affinity for CYT P450 is
• Higher healing rates of lower than omeprazole or  However ,potecy and
 Faster onset of action
erosive esophagitis and lansoprazole:risk of drug efficacy are similar to
better GERD symptoms interactions is minimal. omeprazole .
 Slightly longer t1/2 than
relief is reported.
omeprazole.
• Side effect and drug
 Side effects are similar
interactions similar to •
but drug interactions are
racemic drug .
les significant .
 USES
1. PEPTIC ULCER

2. BLEEDING PEPTIC ULCER

3. STRESS ULCER

4. GASTROESOPHAGEAL REFLUX DISEASE

5. ZOLLINGER-ELLISON SYNDROME

6. ASPIRATION PNEUMONIA
 PEPTIC ULCER

 Omeprazole 20 mg OD is equally or more effective than h2 blockers .

 Relief of pain is rapid and excellent .

 Faster healing has been demonstrated with 40 mg/day .

 Caused healing in of ulcer patient not responding to H2 blockers.

 PPIs are drug of choice for NSAID induced gastric/duodenal ulcer.

 Maintenance PPI treatment reduces recurrence of NSAID associated ulcer.

 STRESS ULCER:

 Intravenous pantoprazole / rabeprazole is an effective

prophylactic for stress ulcers as i.v. H2 blockers .

GASTROESOPHAGEAL REFLUX DISEASE :

 Omeprazole produces more complete round the clock inhibition of gastric acid

resulting in rapid symptom release and is more effective than H2 blockers in

promptly healing of esophageal lesions

 Higher dose than for peptic ulcer or twice daily administration is generally needed.
 ZOLLINGER –ELLISON SYNDROME

 Omeprazole is more effective than h2 blocker in controlling hyperacidity in Z-E

syndrome .

However, 60-120mg/day or more is often required for healing of ulcers.

Inoperable cases have been treated for >6 years with sustained hypersecretory

states like systemic mastocytosis,endocrine adenomas,etc also respond well

 ASPIRATION PNEUMONIA

 PPI are alternative to H2 blockers for prophylaxis of aspiration

pneumonia due to prolonged anesthesia

 H2- Antagonists

 CIMETIDINE
 RANTIDINE
 FAMOTIDINE
 ROXATIDINE

 Cimetidine, Rantidine, Roxatidine – COMPETITIVE INTERACTION

 Famotidiene – COMPETITIVE-NONCOMPETITIVE INTERACTION

CIMETIDINE : first H blocker ;PROTOTYPE

PHARMACOLOGICAL ACTIONS OF
ANTIHISTAMINICS
 H2 BLOCKADE
 H2 antagonist block -
 Histamine-induced gastric secretion
 Cardiac stimulation
 Uterine relaxation (in rat)
 Bronchial relaxation(potentiate HISTAMINE INDUCED
BRONCHOSPASM)
 They are highly selective .
 Attenuate fall in BP due to histamine – a late phase response seen with
high dose
 GASTRIC SECRETION
 Marked inhibition of gastrin secretion.

 All phases of secretions(basal, psychic,neurogenic and gastric)

suppressed dose dependently.

 Secretory responses to all stimuli (histamine,ach,

gastrin,insulin,food) are attenuated.

 Volume ,pepsin content,intrinsic factor secretions are reduced.

 Vitamin B12 absorption not impaired .

 PHARMACOKINETICS
 ROUTE –Orally absorbed
 Bioavailability- 60-70% (due to first pass metabolism)
 Absorption not affected by food in stomach
 Crosses placenta ,reaches milk
 Can sometimes cross blood brain barrier .

 T1/2- 2-3 hrs

 Elimination :2/3 dose unchanged in urine and bile :1/3 oxidized metabolites
 Therefore in renal failure dose reduction is needed
 INTERACTIONS
 Omeprazole inhibits oxidation of certain drugs :diazepam, phenytoin

and warfarin levels may be increased .

 It interferes with activation of clopidogrel by inhibiting CYP2C19 .

 Reduced gastric acidity decreases absorption of ketoconazole and iron

salts .

 Clarithromycin inhibits omeprazole metabolism and increses its plasma

concentration.
 ADVERSE EFFECT
 Cimetidine is well tolerated ;adverse effects occur in <5%.
 Mild side effects includes :
 Headache ,dizziness ,bowel upset , dry mouth, rashes.
 Cimetidine (not other h2 blockers) has –
I. Antiandrogenic action
II. Increases plasma prolactin
III. Inhibits degradation of estradiol by liver .
IV. High doses for prolong time causes gynaecomastia, loss of libido ,impotency
,temporary decrease in sperm count

 INTERACTIONS
i. Cimetidine inhibits several cytochrome p450 enzyme and decreases hepatic blood flow .
ii. It is an enzyme inhibitor : inhibits metabolism of many drugs
a) Warfarin
b) Antipsychotics
c) Lidocaine
d) Nifedipine
e) Sulfonylurea
i. Antacids reduce absorption of all h2 blockers
ii. Ketoconazol absorption is decreased (reduced gastric acidity)
When used concurrently a gap of 2 hrs is required.
 RANITIDINE
• 5 times more potent.
• Pharmacokinetic profile
similar to cimetidine.
• No antiandrogenic action
• No increase in prolactin
secretion
• Less marked effect on hepatic
metabolism.
FAMOTIDINE
• Longer duration of action.
• Some inverse agonistic action
on h2 receptor had been
noted .
• 5-8 times more potent than
ranitidine .
• Antiandrogenic action absent.
• Bioavailability 40-50%.
ROXATIDINE
• Twice as potent and longer
acting than ranitidine .
• Pharmacokinetic profile same
as that of ranitidine.
• No anti androgenic action .
• No cytochrome p450
inhibitory action.

• Incidence off side effects • Considered more potent for

lower . ZE and prevention of
aspiration pneumonia .
• Lesser permeability in brian .
 USES
1. DUODENAL ULCERS

2. GASTRIC ULCERS

3. STRESS ULCERS AND GASTRITIS

4. ZOLLINGER –ELLISON SYNDROME

5. GASTROESOPHAGEAL REFLUX DISEASE

6. PROPHYALAXIX OF ASPIRATION PNEUMONIA

7. CERATIN CASE OF URTICARIA

 Anticholinergics
 Atropine drugs reduce the volume of gastric juice without raising it’s pH.

 Stimulated gastric secretion is less completely inhibited.

 Effective doses for non selective antimuscarinic drugs invariably

produces intolerable side effects.

 PIRENZEPINE: It's used in Europe for peptic ulcer because gastric

secretion is reduced by 40-50% without producing intolerable side

effects.
 Prostaglandin Analogue
 PGE2 and PGI2 are produced in the gastric mucosa.

 They serve as a protective role by inhibiting acid secretion and

promoting mucus as well as HCO3 secretion.

 In addition they:

1. Inhibit gastrin release.

2. Increase mucosal blood flow.
3. Have ill defined “cytoprotective’’ action.
4. It reinforces the mucus layer covering gastric and duodenal mucosa.
ANTACIDS

Speaker- NIKITA PANDEY(54)

Made by-MEGHA KARADWAL(46)

MOHD AZAM(48)
MOHD JUNAID(49)
MOHD NAEEM(50)
NEHA VERMA(53)
 DEFINITION

These are basic substances which

neutralize gastric acid and raise pH of
gastric contents.
 MECHANISM OF ACTION

 In peptic ulcer disease Antacid present a therapeutic

effect by-
Neutralizing acid
Reduce the activity of Reduce the acid
pepsin delivery to duodenum
 POTENCY OF ANTACID

It is defined by acid neutralizing

capacity (ANC) of antacids which is
actually, number of mEq of 1N HCl
that are brought to pH 3.5 in 15 min (or
60 min in some tests) by a unit dose of
the antacid preparation.
 TYPE

SYSTEMIC NON SYSTEMIC

 SODIUM BICARBONATE  MAGNESIUM TRIOXIDE
 SODIUM CITRATE  MAGNESIUM TRISILICATE
 ALUMINIUM HYDROXIDE
GEL
 MAGALDRATE
 CALCIUM CARBONATE
 SYSTEMIC ANTACIDS
1.Sodium bicarbonate
 Potent neutralizer pH may rise above 7.
 Act instantaneously
 Short action of duration

 DISADVANTAGE-
(a) Absorbed systemically: large doses will induce alkalosis.
(b) Produces CO2 in stomach
(c) Acid rebound occurs, but is usually short lasting.
(d) Increases Na+ load
 USES OF SODIUM BICARBONATE-
Casual treatment of heartburn
 Alkalinize urine
 To treat acidosis

2. SODIUM CITRATE
 Properties similar to sod. bicarbonate
 CO2 is not evolved
 NON-SYSTEMIC ANTACIDS

1.MAGNESIUM HYDROXIDE
 Low water solubility
 Its aqueous suspension (milk of magnesia) has low
concentration of OH¯ ions and thus low alkalinity.
 Rebound acidity is mild and brief.
2. ALUMINIUM HYDROXIDE GEL

 Weak and slowly reacting antacid

 Al3+ ions relaxes smooth muscle, thus it delays
gastric emptying
 SIDE EFFECTS

 Constipation
 Osteomalacia
 Aluminium toxicity (encephalopathy, osteoporosis)

 USES
Used therapeutically in hyperphosphatemia and phosphate
stones.
3. CALCIUM CARBONATE

Potent and rapidly acting acid neutralizer
 DRAWBACKS-
 Liberates CO2
 Acid rebound occurs.
 Mild constipation or rarely loose motions may be
produced.
 The absorbed calcium can be dangerous in renal
insufficiency.
4. MAGALDRATE
 It is a hydrated complex of hydroxymagnesium
aluminate that initially reacts rapidly with acid
and releases alum. hydroxide
 Has prompt and sustained neutralizing action.
 Antacid combinations
These may be superior to any single agent on the following
accounts:

Fast (Mag. hydrox.) and slow (Alum. hydrox.) acting

components yield prompt as well as sustained effect.

 Mag. salts are laxative, while alum. salts are constipating

Gastric emptying is least affected

 Dose of individual components is reduced

 DRUG INTERACTIONS

 Tetracyclines  Phenothiazines
 Iron salts  Indomethacin
 Fluoroquinolones  Phenytoin
 Ketoconazole  Isoniazid
 H2 blockers  Ethambutol
 Diazepam  Nitrofurantoin
 ULCER PROTECTIVE
 It incluses sucralfate, colloidal bismuth subcitrate, rebamipide,
ecabet

 Both mucus and epithelial Cell to cell tight junction restrict back
diffusion of acid and pepsin.

 Epithelial mucosal barrier maintain a pH of 7 at mucosal surface.

 Mucosal prostaglandin appear to be important in stimulating

mucus and bicarbonate.
 SUCRALFATE

MECHANISM OF ACTION

 Sucralfate polymerises at pH less than 4 by cross linking of

molecules assuming a sticky gel like consistency

 It strongly adheres to the ulcer base specially duodenal ulcer.

 Surface proteins at ulcer base are precipitated together with

which it acts as a physical barrier.
 DOSE

 1 gram taken in empty stomach 1 hour before the

three major meals and at bedtime for 4 to 8 weeks

 Antacid should not be taken with sucralfate

ULCERFATE, SUCRACE, RECULFATE 1 gm Tab

 SIDE EFFECTS

Constipation
Hypophosphatemia
Dry mouth and nausea are infrequent
 USES

 In ICU as acid suppressant prophylaxis of stress ulcers.

 Intragastric sucralfate as prophylaxis of stress ulcers

without acid suppression is an alternative to IV H2
blocker.
 Interaction

 It interfere with the absorption of tetracycline,

fluoroquinolones, cimetidine, phenytoin ,and digoxin.

 Antacids given concurrently reduce the efficacy of

sucralfate
Colloidal bismuth subcitrate

 It is a water soluble colloidal Bismuth compound but precipitate at ph

less than 5

 Probable mechanism of action :-

> may increase gastric mucosal PGE2 to mucus and bicarbonate

production.
> may precipitate mucus glycoprotein and court the ulcer base.
>main detach and inhibit H. pylori directly .
Uses

 gastritis and non nuclear dyspepsia associated with H. pylori

are also improved by CBS

 DOSE:-
 120mg taken 1/2 hour before 3 major meal and at bedtime for
4-8 weeks

TRYMO, DENOL 120 mg tab.

Side effects

 Diarrhoea, headache and dizziness

 Patient acceptance of CBS is compromised by

blackening of tongue denture and stools and by the
inconvenience of dosing schedule.
Anti- H. pylori Drugs
 HELICOBACTER
PYLORI

75-90% of peptic ulcer are associated with H. pylori infection

Scientific contribution:-
- In 1940, Dr. A. Stone freedberg of Harvard medical school identified unusual curved shaped bacteria
in stomach of ulcers victim
MORPHOLOGY
 H. pylori is spiral shaped gram negative bacteria.
 It has a multiple polar flagella above the pole and motile.
 It is a strong producer of urease.
UREASE
UREA CO2 + NH3
Adaptation to acidic environment of stomach

 Till 1982, it was believed that no bacterium can live in human

stomach
 But later, research found that H. Pylori uses its flagella to burrow
in the mucus lining to reach epithelial cells.
 Epithelial cells are less acidic

 H. Pylori adheres to epithelial cells by producing adhesins.

 It also releases reactive oxygen species which helps in it survival

GOALS

 Eradication of H.pylori concurrently with H2 blockers / PPI

therapy has been associated with --
1-Faster healing
2-Prevents ulcer relapse
 All H. pylori associated ulcers must have H. pylori eradication
therapy.
MANAGEMENT OF
H-PYLORI
 GIVEN FOR 14 DAYS
• CLARITHROMYCIN 500mgBD
• AMOXICILLIN 1g BD
• LANSOPRAZOLE30 mg BD/any PPI
TRIPLE THERAPY REGIMEN
 GIVEN FOR 14 DAYS
• METRONIDAZOLE400mg TDS
• AMOXICILLIN 1g/CLARITHROMYCIN 500 mgBD
• OMEPRAZOLE 2omg BD
QUADRUPLE THERAPY

14 14
DAYS CBS 120mg
DAYS METRONIDAZOLE
QID 400mg TDS

OMEPRAZOLE TETRACYCLINE
20 mg BD 500 mg QID
• DAY 1-14 Amoxicillin1g BD PPIs 14 days
BD
• DAY 7-14 Clarithromycin 500 mg BD+metronidazole
500mg BD
• DAY 1-5 Amoxicillin 1g BD PPIs 10 days
BD
• DAY 6-10 Clarithromycin 500mgBD+metronidazole
500mg BD
SEQUENTIAL QUADRUPLE THERAPY
 Active ulcer not attributable to H-pylori
  Proton pump inhibitors
 Uncomplicated duodenal ulcer: treat for 4 weeks
 Uncomplicated gastric ulcer: treat for 8 weeks  
  H 2-receptor antagonists:
 Uncomplicated duodenal ulcer: cimetidine 800 mg, ranitidine
or nizatidine 300 mg, famotidine 40 mg, orally OD at bedtime for 6
weeks
 Uncomplicated gastric ulcer: cimetidine 400 mg, ranitidine or
nizatidine 150 mg, famotidine 20 mg, orally BD for 8 weeks
 Complicated ulcers: proton pump inhibitors are the preferred drugs
 Peptic ulcer disease

Active H.pylori associated Not associated with H.pylori

SEQUENTIAL 1.Proton pump inhibitors

TRIPLE THERAPY QUADRUPLE
QUADRUPLE THERAPY 2.H2 receptors antagonist
THERAPY
SUMMARY

SPEAKER : Megha Karadwal (46)

MADE BY:Megha Tamta (47)

Kajal Tomar (43)
Pritam Singh (52)
 PEPTIC ULCER occurs in that part of GIT which is exposed to gastric
acid and pepsin i.e. stomach and duodenum.
 SYMPTOMS :
1. Upper abdominal pain
2. Belching
3. Vomiting
4. Weight loss
5. Poor appetite
 Management of peptic ulcer:

 Lifestyle modifications
 Diet management
 Stop consumption of alcohol, NSAIDS
 Stress management
 Smoking cessation
 Anti ulcer therapy
 Drugs for peptic ulcer
1. REDUCTION OF GASTRIC ACID SECRETION
 H2 antihistaminics
 Proton pump inhibitors
 Anticholinergic drugs
 Prostaglandin analogues
2. ANTACIDS
 Systemic
 Non-systemic
3. ULCER PROTECTIVES
4. ANTI H. PYLORI DRUGS
 DRUGS OF CHOICE

CONDITION DRUG OF CHOICE

Gastric ulcer PPI
Duodenal ulcer PPI
Stress ulcer PPI
NSAIDS induced PPI
H. Pylori associated Lansoprazole +
amoxycillin+clarithromycin
ZES PPI
THANK YOU : )